Compare MBBC & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | ANVS |
|---|---|---|
| Founded | 1902 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 48.2M |
| IPO Year | 2020 | 2019 |
| Metric | MBBC | ANVS |
|---|---|---|
| Price | $14.94 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 1.4K | ★ 3.0M |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3200.00 | 39.39 |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $93.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.02 | $0.62 |
| 52 Week High | $15.79 | $5.50 |
| Indicator | MBBC | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 54.18 | 43.86 |
| Support Level | $14.58 | $0.62 |
| Resistance Level | $15.39 | $1.41 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 100.00 | 35.61 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.